{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:37:04Z","timestamp":1777293424544,"version":"3.51.4"},"reference-count":276,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Thoracic malignancies (lung cancers and malignant pleural mesothelioma) are prevalent worldwide and are associated with high morbidity and mortality. Effective treatments are needed for patients with advanced disease. Cell therapies are a promising approach to the treatment of advanced cancers that make use of immune effector cells that have the ability to mediate antitumor immune responses. In this review, we discuss the prospect of chimeric antigen receptor-T (CAR-T) cells, natural killer (NK) cells, T cell receptor-engineered (TCR-T) cells, and tumor-infiltrating lymphocytes (TILs) as treatments for thoracic malignancies. CAR-T cells and TILs have proven successful in several hematologic cancers and advanced melanoma, respectively, but outside of melanoma, results have thus far been unsuccessful in most other solid tumors. NK cells and TCR-T cells are additional cell therapy platforms with their own unique advantages and challenges. Obstacles that must be overcome to develop effective cell therapy for these malignancies include selecting an appropriate target antigen, combating immunosuppressive cells and signaling molecules present in the tumor microenvironment, persistence, and delivering a sufficient quantity of antitumor immune cells to the tumor. Induced pluripotent stem cells (iPSCs) offer great promise as a source for both NK and T cell-based therapies due to their unlimited expansion potential. Here, we review clinical trial data, as well as recent basic scientific advances that offer insight into how we may overcome these obstacles, and provide an overview of ongoing trials testing novel strategies to overcome these obstacles.<\/jats:p>","DOI":"10.3390\/cancers17010035","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T21:13:18Z","timestamp":1735247598000},"page":"35","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Engineered Cellular Therapies for the Treatment of Thoracic Cancers"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-4712","authenticated-orcid":false,"given":"Spencer M.","family":"Erickson","sequence":"first","affiliation":[{"name":"Internal Medicine Residency Program, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8901-5158","authenticated-orcid":false,"given":"Benjamin M.","family":"Manning","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhilesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung Cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/OP.21.00426","article-title":"Management of Advanced Pleural Mesothelioma-At the Crossroads","volume":"18","author":"Nowak","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2022016205","article-title":"Engineered and Banked iPSCs for Advanced NK- and T-Cell Immunotherapies","volume":"141","author":"Cichocki","year":"2023","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. A Preliminary Report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e002723","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive Cellular Therapy in Solid Tumor Malignancies: Review of the Literature and Challenges Ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T Cell Therapy for Patients with Solid Tumours: Key Lessons to Learn and Unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional Delivery of IL-13R\u03b12-Targeting CAR-T Cells in Recurrent High-Grade Glioma: A Phase 1 Trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Caruana","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR Immune Cells: Design Principles, Resistance and the next Generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-Engineered T Cell Therapy in Solid Tumors: State of the Art and Perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic Natural Killer Cell Therapy","volume":"141","author":"Jacobs","year":"2023","journal-title":"Blood"},{"key":"ref_19","first-page":"16","article-title":"Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies","volume":"13","author":"Kiesgen","year":"2018","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Maher, J., and Davies, D.M. (2023). CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens. Biology, 12.","DOI":"10.3390\/biology12020287"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T Cells Targeting CD70 and B7-H3 Exhibit Potent Preclinical Activity against Multiple Solid Tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"ref_22","first-page":"106331","article-title":"Functional Characterization and Development of Novel Human Kinase Insert Domain Receptor Chimeric Antigen Receptor T-Cells for Immunotherapy of Non-Small Cell Lung Cancer","volume":"180","author":"Zhong","year":"2023","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kim, Y.-J., Li, W., Zhelev, D.V., Mellors, J.W., Dimitrov, D.S., and Baek, D.-S. (2023). Chimeric Antigen Receptor-T Cells Are Effective against CEACAM5 Expressing Non-Small Cell Lung Cancer Cells Resistant to Antibody-Drug Conjugates. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1124039"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Porcellini, S., Asperti, C., Corna, S., Cicoria, E., Valtolina, V., Stornaiuolo, A., Valentinis, B., Bordignon, C., and Traversari, C. (2020). CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00099"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1038\/s41388-018-0187-2","article-title":"Antitumor Activity of CD56-Chimeric Antigen Receptor T Cells in Neuroblastoma and SCLC Models","volume":"37","author":"Crossland","year":"2018","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5575260","DOI":"10.1155\/2021\/5575260","article-title":"Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis","volume":"2021","author":"La","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.omto.2020.04.008","article-title":"LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer","volume":"17","author":"Hu","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tranon.2017.10.009","article-title":"Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer","volume":"11","author":"Li","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4049\/jimmunol.2300618","article-title":"Efficacy against Lung Cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor","volume":"212","author":"Toyofuku","year":"2024","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Jie, Y., Liu, G., Feng, L., Li, Y., E, M., Wu, L., Li, Y., Rong, G., Li, Y., and Wei, H. (2021). PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.665970"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Thomas, R., Al-Khadairi, G., Roelands, J., Hendrickx, W., Dermime, S., Bedognetti, D., and Decock, J. (2018). NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00947"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-022-03275-5","article-title":"TCR Extracellular Domain Genetically Linked to CD28, 2B4\/41BB and DAP10\/CD3\u03b6 -Engineered NK Cells Mediates Antitumor Effects","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary \u201cT4 Immunotherapy\u201d of Malignant Mesothelioma Using Pan-ErbB Re-Targeted CAR T-Cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.medj.2023.04.004","article-title":"A Chimeric Antigen Receptor Uniquely Recognizing MICA\/B Stress Proteins Provides an Effective Approach to Target Solid Tumors","volume":"4","author":"Goulding","year":"2023","journal-title":"Med"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/ijc.28857","article-title":"Aberrantly Activated Claudin 6 and 18.2 as Potential Therapy Targets in Non-Small-Cell Lung Cancer","volume":"135","author":"Micke","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural Killer Cell Therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2022410118","DOI":"10.1073\/pnas.2022410118","article-title":"Targeting Loss of Heterozygosity for Cancer-Specific Immunotherapy","volume":"118","author":"Hwang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Byers, L., Heymach, J., Gibbons, D., Zhang, J., Chiappori, A., Rasmussen, E., Decato, B., Smit, M.-A., and Sadraei, N.H. (2022). 697 A Phase 1 Study of AMG 119, a DLL3-Targeting, Chimeric Antigen Receptor (CAR) T Cell Therapy. Relapsed\/Refractory Small Cell Lung Cancer (SCLC), BMJ Publishing Group Ltd.","DOI":"10.1136\/jitc-2022-SITC2022.0697"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/2767-9764.CRC-23-0259","article-title":"Rejuvenated iPSC-Derived GD2-Directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer","volume":"4","author":"Kinoshita","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1038\/s41467-022-33968-5","article-title":"Remodelling of Tumour Microenvironment by Microwave Ablation Potentiates Immunotherapy of AXL-Specific CAR T Cells against Non-Small Cell Lung Cancer","volume":"13","author":"Cao","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e15181","DOI":"10.1200\/JCO.2023.41.16_suppl.e15181","article-title":"Carcinoembryonic Antigen (CEA) Expression in Human Tumors: A Tissue Microarray Study on 15,413 Tumors","volume":"41","author":"Jansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1284722","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in Non-Small-Cell Lung Cancer as Targets of Chimeric Antigen Receptor T Cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41389-020-00257-z","article-title":"Targeting PD-L1 in Non-Small Cell Lung Cancer Using CAR T Cells","volume":"9","author":"Liu","year":"2020","journal-title":"Oncogenesis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.ajpath.2018.05.014","article-title":"Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database","volume":"188","author":"Moek","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"414","DOI":"10.18632\/oncotarget.519","article-title":"Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance","volume":"3","author":"Yu","year":"2012","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of Malignant Pleural Mesothelioma by Fibroblast Activation Protein-Specific Re-Directed T Cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"107356","DOI":"10.1016\/j.lungcan.2023.107356","article-title":"The Search for Therapeutic Targets in Lung Cancer: Preclinical and Human Studies of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Expression and Its Associated Molecular Landscape","volume":"184","author":"Lefebvre","year":"2023","journal-title":"Lung Cancer Amst. Neth."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Knudson, K.M., Hwang, S., McCann, M.S., Joshi, B.H., Husain, S.R., and Puri, R.K. (2022). Recent Advances in IL-13R\u03b12-Directed Cancer Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.878365"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Wang, D.-W., Zhang, W.-H., Danil, G., Yang, K., and Hu, J.-K. (2022). The Role and Mechanism of Claudins in Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1051497"},{"key":"ref_52","first-page":"100630","article-title":"Targeting MET in NSCLC: An Ever-Expanding Territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_53","first-page":"947","article-title":"Targeting Lewis Y (Le(y)) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels","volume":"2","author":"Krug","year":"2007","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/0003-4975(94)00866-6","article-title":"Expression of Lewis-Related Antigen and Prognosis in Stage I Non-Small Cell Lung Cancer","volume":"59","author":"Ogawa","year":"1995","journal-title":"Ann. Thorac. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Engelsen, A.S.T., Lotsberg, M.L., Abou Khouzam, R., Thiery, J.-P., Lorens, J.B., Chouaib, S., and Terry, S. (2022). Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.869676"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5301\/JBM.2011.6291","article-title":"Expression of CD44s and CD44v6 in Lung Cancer and Their Correlation with Prognostic Factors","volume":"26","author":"Afify","year":"2011","journal-title":"Int. J. Biol. Markers"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.humpath.2006.03.014","article-title":"Expression Profile Analysis in Multiple Human Tumors Identifies L1 (CD171) as a Molecular Marker for Differential Diagnosis and Targeted Therapy","volume":"37","author":"Huszar","year":"2006","journal-title":"Hum. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1054\/bjoc.2000.1251","article-title":"NY-ESO-1 Tumour Associated Antigen Is a Cytoplasmic Protein Detectable by Specific Monoclonal Antibodies in Cell Lines and Clinical Specimens","volume":"83","author":"Noppen","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e166028","DOI":"10.1172\/JCI166028","article-title":"IL-18-Secreting CAR T Cells Targeting DLL3 Are Highly Effective in Small Cell Lung Cancer Models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-20-1141","article-title":"Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial","volume":"26","author":"Multhoff","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V Neoantigen Specific T Cell Receptor for Adoptive T Cell Therapy against Tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zajac, P., Schultz-Thater, E., Tornillo, L., Sadowski, C., Trella, E., Mengus, C., Iezzi, G., and Spagnoli, G.C. (2017). MAGE-A Antigens and Cancer Immunotherapy. Front. Med., 4.","DOI":"10.3389\/fmed.2017.00018"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Maher, J., and Davies, D.M. (2023). CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets. Cancers, 15.","DOI":"10.3390\/cancers15041171"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/s41388-024-03060-x","article-title":"Recent Insights into the Therapeutic Strategies Targeting the Pseudokinase PTK7 in Cancer","volume":"43","author":"Dessaux","year":"2024","journal-title":"Oncogene"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.18632\/oncotarget.28132","article-title":"Molecular Characterization of Kita-Kyushu Lung Cancer Antigen (KK-LC-1) Expressing Carcinomas","volume":"12","author":"Hsu","year":"2021","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0169-5002(01)00292-6","article-title":"Prognostic Significance of Tumor Infiltrating Natural Killer Cells Subset CD57 in Patients with Squamous Cell Lung Cancer","volume":"35","author":"Villegas","year":"2002","journal-title":"Lung Cancer Amst. Neth."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ Tumor-Infiltrating Lymphocytes Predict Favorable Prognosis in Malignant Pleural Mesothelioma after Resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of Tumor-Infiltrating T Cells on Survival in Patients with Malignant Pleural Mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/ni1001-957","article-title":"Immunotherapy through TCR Gene Transfer","volume":"2","author":"Kessels","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"eabe2606","DOI":"10.1126\/scisignal.abe2606","article-title":"Comparative Analysis of TCR and CAR Signaling Informs CAR Designs with Superior Antigen Sensitivity and in Vivo Function","volume":"14","author":"Salter","year":"2021","journal-title":"Sci. Signal."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2022.09.022","article-title":"Human Natural Killer Cells: Form, Function, and Development","volume":"151","author":"Mace","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of Natural Killer Cells in Immunity to Cancer, and Applications to Immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful Adoptive Transfer and in Vivo Expansion of Human Haploidentical NK Cells in Patients with Cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nature06534","article-title":"Reprogramming of Human Somatic Cells to Pluripotency with Defined Factors","volume":"451","author":"Park","year":"2008","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1172482","article-title":"Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences","volume":"324","author":"Yu","year":"2009","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-8674(02)00680-3","article-title":"HoxB4 Confers Definitive Lymphoid-Myeloid Engraftment Potential on Embryonic Stem Cell and Yolk Sac Hematopoietic Progenitors","volume":"109","author":"Kyba","year":"2002","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/clpt.2010.341","article-title":"Disease Correction the iPSC Way: Advances in iPSC-Based Therapy","volume":"89","author":"Li","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.stem.2013.09.002","article-title":"Induction of Multipotential Hematopoietic Progenitors from Human Pluripotent Stem Cells via Respecification of Lineage-Restricted Precursors","volume":"13","author":"Doulatov","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nature22370","article-title":"Haematopoietic Stem and Progenitor Cells from Human Pluripotent Stem Cells","volume":"545","author":"Sugimura","year":"2017","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","article-title":"Regeneration of Human Tumor Antigen-Specific T Cells from iPSCs Derived from Mature CD8(+) T Cells","volume":"12","author":"Vizcardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of Rejuvenated Antigen-Specific T Cells by Reprogramming to Pluripotency and Redifferentiation","volume":"12","author":"Nishimura","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.stem.2013.03.001","article-title":"Expansion of Functional Human Mucosal-Associated Invariant T Cells via Reprogramming to Pluripotency and Redifferentiation","volume":"12","author":"Wakao","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-16-1149","article-title":"Regeneration of CD8\u03b1\u03b2 T Cells from T-Cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity","volume":"76","author":"Maeda","year":"2016","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"100998","DOI":"10.1016\/j.isci.2020.100998","article-title":"Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model","volume":"23","author":"Kashima","year":"2020","journal-title":"iScience"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.stemcr.2015.07.011","article-title":"A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy","volume":"5","author":"Ando","year":"2015","journal-title":"Stem Cell Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.stem.2018.10.005","article-title":"Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy","volume":"23","author":"Minagawa","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.cell.2024.01.035","article-title":"A Versatile CRISPR-Cas13d Platform for Multiplexed Transcriptomic Regulation and Metabolic Engineering in Primary Human T Cells","volume":"187","author":"Tieu","year":"2024","journal-title":"Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2022016204","article-title":"Genome-Edited Allogeneic Donor \u201cUniversal\u201d Chimeric Antigen Receptor T Cells","volume":"141","author":"Qasim","year":"2023","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural Killer Cells in Antitumor Adoptive Cell Immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbmt.2017.11.042","article-title":"Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide","volume":"24","author":"Wanquet","year":"2018","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent Stem Cell-Derived NK Cells with High-Affinity Noncleavable CD16a Mediate Improved Antitumor Activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","article-title":"Activation of NK Cell Cytotoxicity","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.4049\/jimmunol.175.8.5095","article-title":"Human Embryonic Stem Cell-Derived NK Cells Acquire Functional Receptors and Cytolytic Activity","volume":"175","author":"Woll","year":"2005","journal-title":"J. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1182\/blood-2008-06-165225","article-title":"Human Embryonic Stem Cells Differentiate into a Homogeneous Population of Natural Killer Cells with Potent in Vivo Antitumor Activity","volume":"113","author":"Woll","year":"2009","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Valamehr, B., Abujarour, R., Robinson, M., Le, T., Robbins, D., Shoemaker, D., and Flynn, P. (2012). A Novel Platform to Enable the High-Throughput Derivation and Characterization of Feeder-Free Human iPSCs. Sci. Rep., 2.","DOI":"10.1038\/srep00213"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-Scale Derivation of Natural Killer Cells from Human Pluripotent Stem Cells for Cancer Therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/stem.2230","article-title":"Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cells Dayt. Ohio"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","article-title":"An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells","volume":"Volume 2048","author":"Zhu","year":"2019","journal-title":"In Vitro Differentiation of T-Cells. Methods in Molecular Biology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.stemcr.2017.10.020","article-title":"Generation of \u201cOff-the-Shelf\u201d Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells","volume":"9","author":"Zeng","year":"2017","journal-title":"Stem Cell Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-Tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ni.3470","article-title":"CIS Is a Potent Checkpoint in NK Cell-Mediated Tumor Immunity","volume":"17","author":"Delconte","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF00199837","article-title":"Tumor-Derived Interleukin-2-Dependent Lymphocytes in Adoptive Immunotherapy of Lung Cancer","volume":"24","author":"Kradin","year":"1987","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(89)91609-7","article-title":"Tumour-Infiltrating Lymphocytes and Interleukin-2 in Treatment of Advanced Cancer","volume":"1","author":"Kradin","year":"1989","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0022-5223(95)70205-9","article-title":"Immunotherapy with the Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 as Adjuvant Treatment in Stage III Non-Small-Cell Lung Cancer. A Pilot Study","volume":"109","author":"Ratto","year":"1995","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00002371-199605000-00007","article-title":"Treatment of Stage IIIB Non-Small-Cell Lung Cancer with Surgery Followed by Infusion of Tumor Infiltrating Lymphocytes and Recombinant Interleukin-2: A Pilot Study","volume":"19","author":"Melioli","year":"1996","journal-title":"J. Immunother. Emphas. Tumor Immunol. Off. J. Soc. Biol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L","article-title":"A Randomized Trial of Adoptive Immunotherapy with Tumor-Infiltrating Lymphocytes and Interleukin-2 versus Standard Therapy in the Postoperative Treatment of Resected Nonsmall Cell Lung Carcinoma","volume":"78","author":"Ratto","year":"1996","journal-title":"Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00002371-200001000-00019","article-title":"Phase II Study of Combined Immunotherapy, Chemotherapy, and Radiotherapy in the Postoperative Treatment of Advanced Non-Small-Cell Lung Cancer","volume":"23","author":"Ratto","year":"2000","journal-title":"J. Immunother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-Infiltrating Lymphocyte Treatment for Anti-PD-1-Resistant Metastatic Lung Cancer: A Phase 1 Trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1126\/science.abl5447","article-title":"Molecular Signatures of Antitumor Neoantigen-Reactive T Cells from Metastatic Human Cancers","volume":"375","author":"Lowery","year":"2022","journal-title":"Science"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00262-024-03710-9","article-title":"Single-Cell Sequencing of Tumour Infiltrating T Cells Efficiently Identifies Tumour-Specific T Cell Receptors Based on the T Cell Activation Score","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"P\u00e9tremand, R., Chiffelle, J., Bobisse, S., Perez, M.A.S., Schmidt, J., Arnaud, M., Barras, D., Lozano-Rabella, M., Genolet, R., and Sauvage, C. (2024). Identification of Clinically Relevant T Cell Receptors for Personalized T Cell Therapy Using Combinatorial Algorithms. Nat. Biotechnol.","DOI":"10.1038\/s41587-024-02232-0"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.immuni.2024.08.014","article-title":"Tumor-Reactive T Cell Clonotype Dynamics Underlying Clinical Response to TIL Therapy in Melanoma","volume":"57","author":"Chiffelle","year":"2024","journal-title":"Immunity"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and Putative Neoantigen Load Predict Clinical Benefit of Adoptive T Cell Therapy in Melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of Patients with EGFR-Expressing Advanced Relapsed\/Refractory Non-Small Cell Lung Cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local Delivery of CAR T Cells Targeting Fibroblast Activation Protein Is Safe in Patients with Pleural Mesothelioma: First Report of FAPME, a Phase I Clinical Trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-Cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I Clinical Trial of EGFR-Specific CAR-T Cells Generated by the piggyBac Transposon System in Advanced Relapsed\/Refractory Non-Small Cell Lung Cancer Patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_121","first-page":"xi12","article-title":"Phase I Clinical Trial of PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Patients with Non-Small Cell Lung Cancer","volume":"30","author":"Lin","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"CT131","DOI":"10.1158\/1538-7445.AM2018-CT131","article-title":"Abstract CT131: A Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies with Defined Subsets of Autologous T Cells Expressing a ROR1-Specific Chimeric Antigen Receptor (ROR1-CAR)","volume":"78","author":"Specht","year":"2018","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T Cells with Cell-Intrinsic PD-1 Checkpoint Blockade Resist Tumor-Mediated Inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-Targeting T Cell Receptor Fusion Construct Cell Therapy in Refractory Solid Tumors: Phase 1\/2 Trial Interim Results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat. Med."},{"key":"ref_127","unstructured":"(2024, September 17). Lyell Immunopharma Conference Call: Initial Clinical and Translational Data from Phase 1 Trial of LYL797, an Enhanced ROR1-Targeted CAR-T Cell Product Candidate. Available online: https:\/\/ir.lyell.com\/static-files\/1a886b99-7757-4074-96f8-8865cb9aed2b."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e003581","DOI":"10.1136\/jitc-2021-003581","article-title":"Phase I Clinical Trial Evaluating the Safety and Efficacy of ADP-A2M10 SPEAR T Cells in Patients with MAGE-A10+ Advanced Non-Small Cell Lung Cancer","volume":"10","author":"Blumenschein","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T Cell Therapy for MAGE-A4+ Solid Cancers in HLA-A*02+ Patients: A Phase 1 Trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/JCO.2023.41.16_suppl.2547","article-title":"Safety and Efficacy of Sleeping Beauty TCR-T Cells Targeting Shared KRAS and TP53 Mutations Expressed by Solid Tumors in First-in-Human Phase 1 Study","volume":"41","author":"Morelli","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e1532759","DOI":"10.1080\/2162402X.2018.1532759","article-title":"Affinity-Enhanced T-Cell Receptors for Adoptive T-Cell Therapy Targeting MAGE-A10: Strategy for Selection of an Optimal Candidate","volume":"8","author":"Border","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular Toxicity and Titin Cross-Reactivity of Affinity-Enhanced T Cells in Myeloma and Melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00262-010-0904-3","article-title":"A Phase I Trial of Adoptive Transfer of Allogeneic Natural Killer Cells in Patients with Advanced Non-Small Cell Lung Cancer","volume":"59","author":"Iliopoulou","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_136","first-page":"2115","article-title":"A Trial of Autologous Ex Vivo-Expanded NK Cell-Enriched Lymphocytes with Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer as Second- or Third-Line Treatment: Phase IIa Study","volume":"33","author":"Yang","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of Patients with Advanced Cancer with the Natural Killer Cell Line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s12026-017-8927-x","article-title":"Clinical Efficacy of Percutaneous Cryoablation Combined with Allogenic NK Cell Immunotherapy for Advanced Non-Small Cell Lung Cancer","volume":"65","author":"Lin","year":"2017","journal-title":"Immunol. Res."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Jia, L., Chen, N., Chen, X., Niu, C., Liu, Z., Ma, K., Wang, N., Yang, L., Zhao, Y., and Song, W. (2022). Sintilimab plus Autologous NK Cells as Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer Previous Treated with Platinum-Containing Chemotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1074906"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1172\/JCI132712","article-title":"Pembrolizumab plus Allogeneic NK Cells in Advanced Non-Small Cell Lung Cancer Patients","volume":"130","author":"Lin","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4143\/crt.2021.986","article-title":"A Phase I\/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1111\/1759-7714.14523","article-title":"Two-Year Efficacy of SNK01 plus Pembrolizumab for Non-Small Cell Lung Cancer: Expanded Observations from a Phase I\/IIa Randomized Controlled Trial","volume":"13","author":"Park","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Patel, S., Patel, M., Gutierrez, M., Anderson, M., Szabo, P., Valamehr, B., Chu, Y.W., Beagle, B., Chou, J., and Hong, D. (2022). 755 Results of a phase I trial of FT500, a first-in-class, off-the-shelf, iPSC\u2013derived NK cell therapy combined with PD-1\/PD-L1 checkpoint blockade therapy and IL-2 in patients with advanced solid tumors. J. ImmunoTherapy Cancer, 10.","DOI":"10.1136\/jitc-2022-SITC2022.0755"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.annonc.2022.01.025","article-title":"17P Driving NK Cell Immunotherapy against NSCLC, in the Context of Hypoxia, Using Tri-Specific Engagers","volume":"33","author":"Miller","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-020-01024-8","article-title":"Targeting B7-H3 via Chimeric Antigen Receptor T Cells and Bispecific Killer Cell Engagers Augments Antitumor Response of Cytotoxic Lymphocytes","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Vallera, D.A., Ferrone, S., Kodal, B., Hinderlie, P., Bendzick, L., Ettestad, B., Hallstrom, C., Zorko, N.A., Rao, A., and Fujioka, N. (2020). NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers, 12.","DOI":"10.3390\/cancers12092659"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Nikkhoi, S.K., Li, G., Eleya, S., Yang, G., Vandavasi, V.G., and Hatefi, A. (2022). Bispecific Killer Cell Engager with High Affinity and Specificity toward CD16a on NK Cells for Cancer Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1039969"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","article-title":"CD16xCD33 Bispecific Killer Cell Engager (BiKE) Activates NK Cells against Primary MDS and MDSC CD33+ Targets","volume":"123","author":"Gleason","year":"2014","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Pawlowski, K.D., Duffy, J.T., Tiwari, A., Zannikou, M., and Balyasnikova, I.V. (2023). Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas. Cells, 12.","DOI":"10.3390\/cells12131716"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11523-015-0391-8","article-title":"Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-Cell Activity Against CD133+ Colorectal Cancer Cells","volume":"11","author":"Schmohl","year":"2016","journal-title":"Target. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e007280","DOI":"10.1136\/jitc-2023-007280","article-title":"iPSC-Derived Natural Killer Cells Expressing the Fc\u03b3R Fusion CD64\/16A Can Be Armed with Antibodies for Multitumor Antigen Targeting","volume":"11","author":"Snyder","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness Enhance Antitumor Activity and Prevent Escape in Solid Tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T Cells Targeting HER2 and IL13R\u03b12 Mitigate Tumor Antigen Escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T Cells through the Solid-Tumour Microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T Cells Secreting BiTEs Circumvent Antigen Escape without Detectable Toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive Cellular Therapy with T Cells Expressing the Dendritic Cell Growth Factor Flt3L Drives Epitope Spreading and Antitumor Immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"eabg3072","DOI":"10.1126\/scitranslmed.abg3072","article-title":"Disrupting N-Glycan Expression on Tumor Cells Boosts Chimeric Antigen Receptor T Cell Efficacy against Solid Malignancies","volume":"14","author":"Greco","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1172\/JCI87624","article-title":"Biopolymers Codelivering Engineered T Cells and STING Agonists Can Eliminate Heterogeneous Tumors","volume":"127","author":"Smith","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional Delivery of Mesothelin-Targeted CAR T Cell Therapy Generates Potent and Long-Lasting CD4-Dependent Tumor Immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T Cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Wang, J., Wang, Y., Pan, H., Zhao, L., Yang, X., Liang, Z., Shen, X., Zhang, J., Yang, J., and Zhu, Y. (2023). Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065424"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41467-022-29647-0","article-title":"Targeting Brain Lesions of Non-Small Cell Lung Cancer by Enhancing CCL2-Mediated CAR-T Cell Migration","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 Expression in CAR-T Cells Improves Immune Cell Infiltration and CAR-T Cell Survival in the Tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41563-024-01825-z","article-title":"Lyophilized Lymph Nodes for Improved Delivery of Chimeric Antigen Receptor T Cells","volume":"23","author":"Shi","year":"2024","journal-title":"Nat. Mater."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic Stroma Restricts T Cell Extravasation and Mediates Immune Exclusion and Immunosuppression in Solid Tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Das, S., Valton, J., Duchateau, P., and Poirot, L. (2023). Stromal Depletion by TALEN-Edited Universal Hypoimmunogenic FAP-CAR T Cells Enables Infiltration and Anti-Tumor Cytotoxicity of Tumor Antigen-Targeted CAR-T Immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1172681"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase Promotes Tumor Infiltration and Antitumor Activity of CAR-Redirected T Lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.18632\/oncotarget.23469","article-title":"HLA Class I Loss and PD-L1 Expression in Lung Cancer: Impact on T-Cell Infiltration and Immune Escape","volume":"9","author":"Perea","year":"2018","journal-title":"Oncotarget"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-Negative TGF-\u03b2 Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e133977","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 Inhibition via CRISPR Promotes the Long-Term Efficacy of CAR T Cells against Solid Tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.chembiol.2023.10.024","article-title":"Genetic Retargeting of E3 Ligases to Enhance CAR T Cell Therapy","volume":"31","author":"Lane","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1158\/0008-5472.CAN-13-1816","article-title":"Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy","volume":"74","author":"Mok","year":"2014","journal-title":"Cancer Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s00262-023-03496-2","article-title":"Blockade of Tumor-Derived Colony-Stimulating Factor 1 (CSF1) Promotes an Immune-Permissive Tumor Microenvironment","volume":"72","author":"Maldonado","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1158\/0008-5472.CAN-13-3583","article-title":"Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment","volume":"74","author":"Cekic","year":"2014","journal-title":"Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the Adenosine 2A Receptor Enhances Chimeric Antigen Receptor T Cell Efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 Mediated Deletion of the Adenosine A2A Receptor Enhances CAR T Cell Efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-Expressing CAR T Cells Resist Dysfunction and Mediate Durable Clearance of Solid Tumors and Metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/2326-6066.CIR-21-0536","article-title":"Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors","volume":"10","author":"Brog","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1038\/s41467-023-40115-1","article-title":"Antigen-Dependent IL-12 Signaling in CAR T Cells Promotes Regional to Systemic Disease Targeting","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e20192203","DOI":"10.1084\/jem.20192203","article-title":"Optimized Gene Engineering of Murine CAR-T Cells Reveals the Beneficial Effects of IL-15 Coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-23-1872","article-title":"Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors That Exhibit Augmented Activity against Advanced Solid Tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 Engineering Improves CAR T Cell Function in Solid Tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","article-title":"Synthetic Cytokine Circuits That Drive T Cells into Immune-Excluded Tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1158\/0008-5472.CAN-22-2220","article-title":"Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors","volume":"83","author":"Zhong","year":"2023","journal-title":"Cancer Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1182\/blood-2011-10-386482","article-title":"Levels of Peripheral CD4(+)FoxP3(+) Regulatory T Cells Are Negatively Associated with Clinical Response to Adoptive Immunotherapy of Human Cancer","volume":"119","author":"Yao","year":"2012","journal-title":"Blood"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"eabg8693","DOI":"10.1126\/scitranslmed.abg8693","article-title":"Dual Targeting of CTLA-4 and CD47 on Treg Cells Promotes Immunity against Solid Tumors","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of Acute Myeloid Leukemia by Haploidentical Natural Killer Cells Is Improved Using IL-2 Diphtheria Toxin Fusion Protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of Homeostatic Cytokine Sinks by Lymphodepletion Enhances the Efficacy of Adoptively Transferred Tumor-Specific CD8+ T Cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy When Combined with Checkpoint Blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Luo, W., Napoleon, J.V., Zhang, F., Lee, Y.G., Wang, B., Putt, K.S., and Low, P.S. (2022). Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.816761"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Srivastava, M.K., Zhu, L., Harris-White, M., Kar, U.K., Huang, M., Johnson, M.F., Lee, J.M., Elashoff, D., Strieter, R., and Dubinett, S. (2012). Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer. PLoS ONE, 7.","DOI":"10.2147\/ITT.S32617"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","article-title":"The Immunostimulatory RNA RN7SL1 Enables CAR-T Cells to Enhance Autonomous and Endogenous Immune Function","volume":"184","author":"Johnson","year":"2021","journal-title":"Cell"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1016\/j.cell.2024.08.029","article-title":"Intercellular Nanotube-Mediated Mitochondrial Transfer Enhances T Cell Metabolic Fitness and Antitumor Efficacy","volume":"187","author":"Baldwin","year":"2024","journal-title":"Cell"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41467-022-35583-w","article-title":"Deletion of SNX9 Alleviates CD8 T Cell Exhaustion for Effective Cellular Cancer Immunotherapy","volume":"14","author":"Trefny","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41586-024-07018-7","article-title":"Naturally Occurring T Cell Mutations Enhance Engineered T Cell Therapies","volume":"626","author":"Garcia","year":"2024","journal-title":"Nature"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","article-title":"Circadian Tumor Infiltration and Function of CD8+ T Cells Dictate Immunotherapy Efficacy","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T Cells Mediate Response of Adoptive Cell Immunotherapy against Human Cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 Enhances CAR T Cell Stemness, Metabolic Fitness and Efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 Is a Master Regulator of Memory Programming in CAR T Cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"e20232368","DOI":"10.1084\/jem.20232368","article-title":"Induction of Immortal-like and Functional CAR T Cells by Defined Factors","volume":"221","author":"Wang","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","article-title":"Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy","volume":"23","author":"Sukumar","year":"2016","journal-title":"Cell Metab."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Berahovich, R., Liu, X., Zhou, H., Tsadik, E., Xu, S., Golubovskaya, V., and Wu, L. (2019). Hypoxia Selectively Impairs CAR-T Cells In Vitro. Cancers, 11.","DOI":"10.3390\/cancers11050602"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Juillerat, A., Marechal, A., Filhol, J.M., Valogne, Y., Valton, J., Duclert, A., Duchateau, P., and Poirot, L. (2017). An Oxygen Sensitive Self-Decision Making Engineered CAR T-Cell. Sci. Rep., 7.","DOI":"10.1038\/srep39833"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"100227","DOI":"10.1016\/j.xcrm.2021.100227","article-title":"Hypoxia-Sensing CAR T Cells Provide Safety and Efficacy in Treating Solid Tumors","volume":"2","author":"Kosti","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s40425-019-0685-y","article-title":"PD-1 Silencing Impairs the Anti-Tumor Function of Chimeric Antigen Receptor Modified T Cells by Inhibiting Proliferation Activity","volume":"7","author":"Wei","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the Inhibitory Co-Receptor CTLA-4 Enhances and Invigorates Chimeric Antigen Receptor T Cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1084\/jem.20150304","article-title":"Cish Actively Silences TCR Signaling in CD8+ T Cells to Maintain Tumor Tolerance","volume":"212","author":"Palmer","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_215","first-page":"A359","article-title":"333 Targeting the Apical Intracellular Checkpoint CISH Unleashes T Cell Neoantigen Reactivity and Effector Program","volume":"8","author":"Palmer","year":"2020","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Dash, A.S., and Patel, M.R. (2017). Viroimmunotherapy of Thoracic Cancers. Biomedicines, 5.","DOI":"10.3390\/biomedicines5010002"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"104041","DOI":"10.1016\/j.cellimm.2020.104041","article-title":"Oncolytic Adenovirus Targeting TGF-\u03b2 Enhances Anti-Tumor Responses of Mesothelin-Targeted Chimeric Antigen Receptor T Cell Therapy against Breast Cancer","volume":"348","author":"Li","year":"2020","journal-title":"Cell. Immunol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"e988098","DOI":"10.4161\/21505594.2014.988098","article-title":"Oncolytic Virus Expressing RANTES and IL-15 Enhances Function of CAR-Modified T Cells in Solid Tumors","volume":"4","author":"Nishio","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective Combination Immunotherapy Using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic Virus-Mediated Expansion of Dual-Specific CAR T Cells Improves Efficacy against Solid Tumors in Mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR-T Cell Activity against Solid Tumors by Vaccine Boosting through the Chimeric Receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-Boosted CAR T Crosstalk with Host Immunity to Reject Tumors with Antigen Heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA Vaccine Drives Expansion and Efficacy of Claudin-CAR-T Cells against Solid Tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-Expression of CD39 and CD103 Identifies Tumor-Reactive CD8 T Cells in Human Solid Tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1158\/1078-0432.CCR-16-2680","article-title":"Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression","volume":"23","author":"Parkhurst","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Tan, C.L., Lindner, K., Boschert, T., Meng, Z., Rodriguez Ehrenfried, A., De Roia, A., Haltenhof, G., Faenza, A., Imperatore, F., and Bunse, L. (2024). Prediction of Tumor-Reactive T Cell Receptors from scRNA-Seq Data for Personalized T Cell Therapy. Nat. Biotechnol.","DOI":"10.1038\/s41587-024-02161-y"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","article-title":"A Phenotypic Signature That Identifies Neoantigen-Reactive T Cells in Fresh Human Lung Cancers","volume":"40","author":"Hanada","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1038\/s41467-024-46906-4","article-title":"Uveal Melanoma Immunogenomics Predict Immunotherapy Resistance and Susceptibility","volume":"15","author":"Bhaskarla","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature10803","article-title":"Expression of Tumour-Specific Antigens Underlies Cancer Immunoediting","volume":"482","author":"DuPage","year":"2012","journal-title":"Nature"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-Directed Immune Escape in Lung Cancer Evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","article-title":"Targeting of Multiple Tumor-Associated Antigens by Individual T Cell Receptors during Successful Cancer Immunotherapy","volume":"186","author":"Dolton","year":"2023","journal-title":"Cell"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/1078-0432.CCR-23-2905","article-title":"One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication","volume":"30","author":"Wolf","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41551-021-00820-y","article-title":"Efficient Recovery of Potent Tumour-Infiltrating Lymphocytes through Quantitative Immunomagnetic Cell Sorting","volume":"6","author":"Wang","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"e008645","DOI":"10.1136\/jitc-2023-008645","article-title":"Neoantigen-Specific Stimulation of Tumor-Infiltrating Lymphocytes Enables Effective TCR Isolation and Expansion While Preserving Stem-like Memory Phenotypes","volume":"12","author":"Levin","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"e003826","DOI":"10.1136\/jitc-2021-003826","article-title":"Mesothelin-Specific CAR-T Cell Therapy That Incorporates an HLA-Gated Safety Mechanism Selectively Kills Tumor Cells","volume":"10","author":"Tokatlian","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"298","DOI":"10.5582\/bst.2018.01048","article-title":"Bi-Specific Ligand-Controlled Chimeric Antigen Receptor T-Cell Therapy for Non-Small Cell Lung Cancer","volume":"12","author":"Chu","year":"2018","journal-title":"Biosci. Trends"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In Vivo CAR T-Cell Generation in Nonhuman Primates Using Lentiviral Vectors Displaying a Multidomain Fusion Ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-Mediated in Vivo CAR Gene Therapy for Targeting Human T-Cell Leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In Vivo Human T Cell Engineering with Enveloped Delivery Vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41541-023-00713-y","article-title":"A Systematic Safety Pipeline for Selection of T-Cell Receptors to Enter Clinical Use","volume":"8","author":"Foldvari","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"e2312057120","DOI":"10.1073\/pnas.2312057120","article-title":"Structural and Physical Features That Distinguish Tumor-Controlling from Inactive Cancer Neoepitopes","volume":"120","author":"Custodio","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/s41467-024-46367-9","article-title":"Structural Basis for Self-Discrimination by Neoantigen-Specific TCRs","volume":"15","author":"Finnigan","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"e2216697120","DOI":"10.1073\/pnas.2216697120","article-title":"Peptide-Binding Specificity Prediction Using Fine-Tuned Protein Structure Prediction Networks","volume":"120","author":"Motmaen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting Immunogenic Tumour Mutations by Combining Mass Spectrometry and Exome Sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"2182058","DOI":"10.1080\/2162402X.2023.2182058","article-title":"Mesothelin-Targeting T Cells Bearing a Novel T Cell Receptor Fusion Construct (TRuC) Exhibit Potent Antitumor Efficacy against Solid Tumors","volume":"12","author":"Ding","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","article-title":"Immune Checkpoint Molecules in Natural Killer Cells as Potential Targets for Cancer Immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"eaaz5618","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-Derived NK Cells Maintain High Cytotoxicity and Enhance in Vivo Tumor Control in Concert with T Cells and Anti-PD-1 Therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2013-08-519199","article-title":"Anti-KIR Antibody Enhancement of Anti-Lymphoma Activity of Natural Killer Cells as Monotherapy and in Combination with Anti-CD20 Antibodies","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking Expression of Inhibitory Receptor NKG2A Overcomes Tumor Resistance to NK Cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a Cytokine Checkpoint Enhances the Fitness of Armored Cord Blood CAR-NK Cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb Is a Checkpoint Inhibitor That Promotes Anti-Tumor Immunity by Unleashing Both T and NK Cells","volume":"175","author":"Denis","year":"2018","journal-title":"Cell"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"e007502","DOI":"10.1136\/jitc-2023-007502","article-title":"Knockout of the Inhibitory Receptor TIGIT Enhances the Antitumor Response of Ex Vivo Expanded NK Cells and Prevents Fratricide with Therapeutic Fc-Active TIGIT Antibodies","volume":"11","author":"Hasan","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.aao0505","article-title":"Antibody-Mediated Inhibition of MICA and MICB Shedding Promotes NK Cell-Driven Tumor Immunity","volume":"359","author":"Tay","year":"2018","journal-title":"Science"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/2326-6066.CIR-19-0483","article-title":"Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells","volume":"8","author":"Kumar","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/s41467-024-46778-8","article-title":"BET Inhibitors Drive Natural Killer Activation in Non-Small Cell Lung Cancer via BRD4 and SMAD3","volume":"15","author":"Reggiani","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","article-title":"Augmenting NK Cell-Based Immunotherapy by Targeting Mitochondrial Apoptosis","volume":"185","author":"Pan","year":"2022","journal-title":"Cell"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"e14518","DOI":"10.1200\/JCO.2024.42.16_suppl.e14518","article-title":"Next Generation CD44v6-Specific CAR-NK Cells for the Treatment of Solid Tumors","volume":"42","author":"Pecher","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 Cells Targeting DLL3 Kill Effectively Small Cell Lung Cancer Cells in Vitro and in Vivo","volume":"112","author":"Liu","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2020.04.016","article-title":"A Novel Chimeric PD1-NKG2D-41BB Receptor Enhances Antitumor Activity of NK92 Cells against Human Lung Cancer H1299 Cells by Triggering Pyroptosis","volume":"122","author":"Lu","year":"2020","journal-title":"Mol. Immunol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"e003715","DOI":"10.1136\/jitc-2021-003715","article-title":"T Cell Receptor Engineering of Primary NK Cells to Therapeutically Target Tumors and Tumor Immune Evasion","volume":"10","author":"Morton","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ebiom.2019.01.031","article-title":"NK Cells Specifically TCR-Dressed to Kill Cancer Cells","volume":"40","author":"Mensali","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","article-title":"NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors","volume":"7","author":"Parihar","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1073\/pnas.0813192106","article-title":"Cytokine-Induced Memory-like Natural Killer Cells","volume":"106","author":"Cooper","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-Induced Memory-like Natural Killer Cells Exhibit Enhanced Responses against Myeloid Leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"CT540","DOI":"10.1158\/1538-7445.AM2022-CT540","article-title":"Abstract CT540: A Phase 1 Trial of Cytokine-Induced Memory-like (CIML) Natural Killer (NK) Cell Therapy with IL-15 Superagonist in Advanced Head and Neck Cancer: Part 1 Results","volume":"82","author":"Hanna","year":"2022","journal-title":"Cancer Res."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"14725","DOI":"10.1073\/pnas.1110900108","article-title":"Expansion of a Unique CD57+NKG2Chi Natural Killer Cell Subset during Acute Human Cytomegalovirus Infection","volume":"108","author":"Milush","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.immuni.2015.02.008","article-title":"Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function","volume":"42","author":"Schlums","year":"2015","journal-title":"Immunity"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/0008-5472.CAN-16-0839","article-title":"Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells","volume":"76","author":"Sarhan","year":"2016","journal-title":"Cancer Res."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/2326-6066.CIR-17-0498","article-title":"Adaptive NK Cells Resist Regulatory T-Cell Suppression Driven by IL37","volume":"6","author":"Sarhan","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.stem.2021.08.013","article-title":"Harnessing Features of Adaptive NK Cells to Generate iPSC-Derived NK Cells for Enhanced Immunotherapy","volume":"28","author":"Woan","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"e007955","DOI":"10.1136\/jitc-2023-007955","article-title":"Therapeutic Avenues for \u0393\u03b4 T Cells in Cancer","volume":"11","author":"Costa","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/35\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:00:33Z","timestamp":1760115633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":276,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17010035"],"URL":"https:\/\/doi.org\/10.3390\/cancers17010035","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]}}}